Vaccitech plc (VACC) News
Filter VACC News Items
VACC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VACC News Highlights
- For VACC, its 30 day story count is now at 2.
- Over the past 8 days, the trend for VACC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- KYMR are the most mentioned tickers in articles about VACC.
Latest VACC News From Around the Web
Below are the latest news stories about VACCITECH PLC that investors may wish to consider to help them evaluate VACC as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start off the week with a breakdown of the biggest pre-market stock movers that investors need to know about for Monday! |
Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?Kymera Therapeutics, Inc. (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
Vaccitech plc (NASDAQ:VACC) surges 85%; individual investors who own 44% shares profited along with institutionsKey Insights Significant control over Vaccitech by individual investors implies that the general public has more power... |
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection and po |
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsOXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company’s progress. “In the second quarter of 2023, Vaccitech achieved importa |
Vaccitech (NASDAQ:VACC) shareholders have endured a 50% loss from investing in the stock a year agoPassive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active... |
Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains?Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Vaccitech (NASDAQ:VACC) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis BMeaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a low-dose PD-1 inhibitorTwo patients developed a non-detectable HBsAg level, which continued eight months after last doseA robust T cell response was generated and was highest in participants who received VTP-300 aloneVTP-300 led to a decline in HBsAg in adults with chronic Hepatitis B with either genotype B or C viruses. VTP-300-elicited T cells have shown cross-reactivity |
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal AntibodyEvaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first patient has been dosed in the additional treatment arm of the AB-729 Phase 2a tr |